A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin

Pre-clinical studies indicate that cisplatin encapsulated in STEALTH®liposomes (SPI-77) retains anti-tumour activity, but has a much reduced toxicity, compared to native cisplatin. A phase I study was conducted to determine the toxicity and pharmacokinetics of SPI-77 administered to children with ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Veal, G J, Griffin, M J, Price, E, Parry, A, Dick, G S, Little, M A, Yule, S M, Morland, B, Estlin, E J, Hale, J P, Pearson, A D J, Welbank, H, Boddy, A V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363870/
https://www.ncbi.nlm.nih.gov/pubmed/11308249
http://dx.doi.org/10.1054/bjoc.2001.1723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363870/
https://www.ncbi.nlm.nih.gov/pubmed/11308249
http://dx.doi.org/10.1054/bjoc.2001.1723

Ejemplares similares